|
|
Article: Insomnia drugs assessed by NIH consensus panel.(Psychiatry)
- Article from:
- Internal Medicine News
- Article date:
- July 15, 2005
- Author:
CopyrightCOPYRIGHT 2005 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
New benzodiazepine receptor agonists for chronic insomnia--zaleplon, zolpidem, and eszopiclone--have shown fewer adverse effects compared with other medications, but additional studies are needed to assess these drugs' long-term effectiveness, concluded members of an independent panel convened by the National Institutes of Health in Bethesda, Md.
Only eszopiclone (Lunesta) has been approved for the long-term treatment of insomnia; other drugs are approved for up to 35 days of use. Five benzodiazepines--estazolam, flurazepam, quazepam, temazepam, and triazolam--also are approved by the Food and Drug Administration to treat insomnia, but adverse events including ...